27 January 2016
: Case report
IFN beta 1a as Glucocorticoids-Sparing Therapy in a Patient with CLIPPERS
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Unexpected drug reaction, Rare disease, Educational Purpose (only if useful for a systematic review or synthesis)
María RicoEF, Javier VillafaniEF, Alberto TuñónEF, Valentín MateosEF, Pedro Oliva-NacarinoEFDOI: 10.12659/AJCR.896102
Am J Case Rep 2016; 17:47-50
Abstract
BACKGROUND: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) is a recently described inflammatory disease of the central nervous system, distinguished by brainstem- and spinal cord-centered lesions with a characteristic contrast enhancement on MRI, a lymphocytic perivascular infiltrate on pathological exam, and a dramatic response to and dependence on steroids therapy. Since its initial description in 2010, different glucocorticoid-sparing agents, mostly immunosuppressant drugs, have been used to minimize the dosage, but these therapies also carry the risk of important secondary effects. We present the first reported case of CLIPPERS treated with interferon beta 1a as add-on therapy.
CASE REPORT: A previously healthy 31-year-old man presented with gait ataxia and dysarthria. MRI showed pons-centered hyperintense patchy lesions on T2-weighted images. Additional tests ruled out other possible diagnoses and symptoms reversed with intravenous methylprednisolone. Over the years the patient presented with several episodes of deterioration each year, which were partly reversed with glucocorticoid therapy, but leaving him with growing sequelae. Four years after the initial event, treatment with interferon-beta-1a was initiated, achieving reduced frequency of the relapses to 1 every 4 years, which were no longer associated to increasing disability. This allowed reducing glucocorticoids to 30 mg of Deflazacort every other day.
CONCLUSIONS: Interferon beta-1a could be an alternative to corticosteroid-combined therapy in CLIPPERS and its more benign profile of secondary effects compared to immunosuppressants could make it an attractive choice.
Keywords: Adjuvants, Immunologic - therapeutic use, Anti-Inflammatory Agents - administration & dosage, Encephalomyelitis - drug therapy, Interferon beta-1a - therapeutic use, Lymphatic Diseases - drug therapy, Magnetic Resonance Imaging, Pons - pathology, Pregnenediones - administration & dosage
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946588
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946011
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945910
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945852
Most Viewed Current Articles
21 Jun 2024 : Case report
88,859
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,114
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,398
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,663
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030